• Salman K. Ajlan Department of Biochemistry, College of Medicine, University of Basrah
  • lamia M. Al – Naama Department of Biochemistry, College of Medicine, University of Basrah
  • Mariam S. Mahmood Clinical Biochemistry Laboratory, Basrah Maternity and Children Hospital, Basrah.
Keywords: Diabetes mellitus, glycaemic control, HA1c


Objective: To evaluate the degree of glycaemic control  among diabetic patients. Methods: The study included 156 diabetic patients (64 with insulin – dependent diabetes mellitus (IDDM) and 92 with non insulin – dependent diabetes mellitus ( NIDDM) ), and 120 control subject. The parameters measured were fasting blood glucose (FBG) and the level of glycated haemoglobin (Hb A1c). Results: HbA1c level was significantly higher among diabetic patients (both IDDM and NIDDM) compared to controls (P<0.001). Also, 43.8% of IDDM patients and 63.0% of NIDDM patients were in poor glycaemic control. Conclusion: substantial proportion of diabetic patients are in poor metabolic control , and hence, more prone to early diabetic complications.


World Health Organization. Manual on diabetes in primary health care. Regional office for the Eastern Mediterranean, 1995.

Fries BM, Truswell AS, Shepherd J, et al. Diabetes mellitus and nutritional and metabolic disorders. In: Haslett C, Chilvers ER, Hunter JAA, et al, eds. Davidson’s Principles and Practice of Medicine. 18th edn, Edinburgh: Churchill Livingstone, 1999: 471-542.

Sherwin RS. Diabetes mellitus. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 23rd edn, Philadelphia: W.B.saunders Company, 2007: 1263-1285.

Gale EAM, Anderson JV. Diabetes mellitus and other disorders of metabolism. In: Kumar P, Clark M, eds. Clinical Medicine. 6th edn, Edinburgh: Elsevier Saunders, 2005:1101 – 1151.

Brancati FL, Kao WH, Folsom AR, et al. Incident type 2 diabetes mellitus in African-American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000; 283:2253–2259.

Jencks SF, Cuerdon T, Burwen DR, et al : Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA 2000; 284:1670–1676.

American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 2002; 25(Suppl. 1): S74–S77.

Visona A, Lusiain L, Bonanome A, et al. Well thickening of common carotid arteries in patients affected by non-insulin dependent diabetes mellitus: relationship to microvascular complications. Angiology 1995; 46: 793-799.

Davidson’s JK. Clinical diabetes mellitus. A problem oriented approach. New York. Thieme Inc, 1986.

Spicer KM, Allen RC, Hallet D, et al. Synthesis of heamoglobin A1c and related minor heamoglobins by erythrocytes. In vivo study of regulation. J Clin Invest 1977; 64: 40-46.

Bunn HF, Gabby KH, Gallop PM. The glycosylation of haemoglobin: Relevance to diabetes mellitus. Science 1978; 200: 21-27.

Ikeda, T Ochi H, Ohtani I, et al. Serum lipid and lipoprotein levels in non hypertensive lean NIDDM patients, J Intern Med 1991; 230: 131-134.

Virtanen SM, Rasanen L, Virtanen M, et al Association of serum lipids with metabolic control and diet in young subjects with insulin dependent diabetes mellitus in Finland. Eur J clin Nutr 1993; 47: 141-149.

Azab AS. glycaemic control among diabetic patients. Saudi Med J 2001; 22: 407-409.

Davis TM. Ethnic diversity in type 2 diabetes. Diabet Med 2008 ; 25 (Suppl 2) :52-56.

Gary TL, McGuire M, McCauley J, et al. Racial comparisons of health care and glycemic control for African American and white diabetic adults in an urban managed care organization. Dis Manag 2004 ;7: 25-34.

de Rekeneire N, Rooks RN, Simonsick EM, et al. Racial differences in glycemic control in a well-functioning older diabetic population: findings from the Health, Aging and Body Composition Study. Diabetes Care 2003 ;26:1986-1992.

Eckel RH, Albers JJ, Cheung MC, et al. High density lipoprotein composition in insulin dependent diabetes mellitus. Diabetes 1981; 30: 132-138.

Lopes-Virella MF, Wohlthann HJ, Mayfield RK, et al. Effect of metabolic control on lipid, lipoprotein and apolipoprotein levels in 55 insulin dependent diabetic patients. A longitudinal study. Diabetes 1983; 32: 20-25.

Ginsberg HN. Lipoprotein physiology in non-diabetic and diabetic states. Relationship to atherosclerosis. Diabetes care 1991; 14: 839-855.

Brown WV. Lipoprotein disorders in diabetes mellitus. Med J Clin North Am 1994; 78: 143-161.

Guerci B, Igau B, Ziegler O, et al. Intraperitoneal insulin infusion improves the depletion in choline containing phospholipids of lipoprotein B particles in type 1 diabetic patients. Metabolism 1996; 45: 430-434.

Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes. Diabetes 1992, 41 (suppl 2): 12-17.

Dailey GE , Mohideen P, Fiedorek FT. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. Clin Ther 2002 ;24:1426-1438.

Erdman DM, Cook CB, Greenlund KJ, et al. The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes. Diabetes Care 2002; 25: 9 – 15.

Robinson AC, Burke J, Robinson S, et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998 ;21:701-705.

Wulffelé MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004 ;256:1-14.

Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002 ;89: 50C-57C.

Santini E, Madec S, Corretti V, et al. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J Endocrinol Invest 2008; 31: 660-665.

Harley CR, Gandhi S, Blasetto J, et al. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother 2007 ;5:185-194.

Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007;67:121-153.

Tenenbaum A, Fisman EZ, Motro M, Adler Y.Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 2008;45:127-53.

Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the Development of Diabetes Mellitus. Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362.

Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin dependent diabetes mellitus. Am J Med 1996; 28: 341-343.

Iribarren C, MD, Karter AJ, Go AS., MD, et al . Glycemic Control and Heart Failure Among Adult Patients With Diabetes. Circulation 2001;103:2668-2673.